Pharmaceutical

Sandoz launches ustekinumab biosimilar in Europe 

Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Samsung Bioepis to treat psoriasis and Crohn’s disease.

Jul 26, 2024 - 04:00
Sandoz launches ustekinumab biosimilar in Europe 
Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Samsung Bioepis to treat psoriasis and Crohn’s disease.
Read the original article

Tags:

Previous Article

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy

Next Article

ConSynance wins FDA designation for Prader-Willi syndrome therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Silence announces $120m private placement for depositary shares

Silence announces $120m private placement for depositar...

Feb 6, 2024

Bristol Myers Squibb’s Breyanzi receives EC approval to treat LBCL

Bristol Myers Squibb’s Breyanzi receives EC approval to...

May 4, 2023

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

Lilly touts Omvoh’s superiority over J&J’s Stelara in C...

Oct 16, 2024